allogeneic– tag –
-
Fate Therapeutics to Present Encore Clinical Data for iPSC-Derived FT819 in Systemic Scleroderma
Fate Therapeutics, Inc. Investors USA Overview Fate Therapeutics will re-present clinical data for FT819, its iPSC-derived, off-the-shelf CAR T-cell product candidate, at the CCR – West 2026 conference. The data potentially shows early c... -
Allogeneic Cell Therapy Manufacturing: Challenges, Advantages, and the Key Role of Automated Bioreactors for Scalability
sdg.azte.co Global Overview This article delves into the complexities of allogeneic cell therapy manufacturing, highlighting its advantages such as scalability, off-the-shelf availability, and cost-effectiveness. The manufacturing proces... -
GentiBio Publishes in EMBO Molecular Medicine, Detailing Technology Enabling Durable Persistence of Allogeneic T-Cell Therapies
GentiBio (Press Release) USA Overview GentiBio announced the publication in EMBO Molecular Medicine of a paper detailing an innovative technology enabling durable in vivo persistence of allogeneic T-cell therapies. This approach addresse... -
TScan Therapeutics Pivots to In Vivo TCR-T Therapy, Halting Allogeneic Cell Program TSC-101 Amidst Manufacturing Challenges
FirstWord Pharma USA Overview TScan Therapeutics announced a strategic pivot, discontinuing its lead allogeneic cell therapy program, TSC-101, and shifting focus to preclinical in vivo TCR-T candidates for solid tumors, citing funding co... -
Functional Polymer FP003B Maximizes Cell Yield in Microcarrier MSC Culture by Suppressing Aggregation, Frontiers Reports Breakthrough
Frontiers Switzerland Overview A new study in Frontiers proposes a breakthrough method using functional polymer 003B (FP003B) to significantly inhibit excessive aggregation of microcarriers/mesenchymal stromal cells (MSCs) and enhance ce... -
Technology Networks Delineates Commercialization Strategies for iPSC Therapies: Automated Manufacturing and Immune-Evasive Cell Line Development are Key
Technology Networks UK Overview Technology Networks provides an in-depth analysis of strategic challenges and solutions for the commercial viability of iPSC-based therapies, emphasizing the critical importance of scalable manufacturing, ... -
T-MAXIMUM Allogeneic CAR T-Therapy MT027 Receives FDA Fast Track Designation for Recurrent Glioblastoma
PR Newswire USA Overview T-MAXIMUM PHARMACEUTICAL announced that its B7-H3-targeted allogeneic CAR T-cell therapy, MT027, has received Fast Track Designation (FTD) from the U.S. FDA for the treatment of recurrent glioblastoma. MT027 had ... -
REPROCELL Accelerates Clinical Production with FDA/EMA/PMDA-Compliant iPSC Manufacturing Platform
REPROCELL Japan Overview REPROCELL has unveiled a robust iPSC manufacturing scale-up strategy aimed at accelerating clinical development and commercialization of iPSC-based therapeutics. Their StemRNA™ Clinical iPSC Platform offers clini... -
Northway Biotech Inaugurates €61 Million Cell Therapy CDMO Facility in Vilnius, First in the Baltics
PR Newswire Lithuania Overview Northway Biotech has invested €61 million to establish the Baltic states' first large-scale Contract Development and Manufacturing Organization (CDMO) facility for cell therapy and personalized medicine in ... -
The Medicine Maker Forecasts Commercial-Scale iPSC Cell Therapy Hinges on Allogeneic Advances and Manufacturing Bottleneck Resolution
The Medicine Maker UK Overview The Medicine Maker reports that commercial-scale iPSC cell therapy hinges on the evolution of allogeneic cell therapies and the resolution of manufacturing bottlenecks. Stefan Braam, CTO of Cellistic, discu...
